2008 News Releases
Nov 18, 2008:
iCo Therapeutics Oral Amphotericin B Poster at AAPS
Nov 17, 2008:
iCo Therapeutics Third Quarter Financial Results
Nov 7, 2008:
iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis
Oct 9, 2008:
iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results
Oct 1, 2008:
iCo Therapeutics Selected as Canada's Top 10TM Competition Winner
Sep 29, 2008:
iCo Therapeutics to Present at BioContact Québec
Sep 22, 2008:
iCo Therapeutics Provides Interim Trial Results (Diffuse Diabetic Macular Edema)
Sep 4, 2008:
iCo Therapeutics Outlines Steps to First iCo-009 Human Clinical Trial
Aug 28, 2008:
iCo Therapeutics Second Quarter Financial Results
Jul 8, 2008:
iCo Therapeutics Appoints Mr. Noel Hall and Dr. Christian Fibiger to Board
Jun 26, 2008:
iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results
Jun 9, 2008:
iCo Therapeutics Closes $1,140,450 Financing
Jun 2, 2008:
iCo Therapeutics Announces $1,140,450 Financing
May 30, 2008:
iCo Therapeutics First Quarter Financial Results
May 7, 2008:
iCo Therapeutics Acquires Worldwide Rights to iCo-009 (Oral Amphotericin B)
May 5, 2008:
iCo Therapeutics to Present at BioFinance 2008
Apr 28, 2008:
iCo Therapeutics Year-End 2007 Financial Results
Apr 25, 2008:
iCo Therapeutics iCo-007 Diabetic Macular Edema Poster Presentation at ARVO
Apr 21, 2008:
iCo Therapeutics Announces iCo-009 (Oral Amphotericin B) FDA Meeting
Mar 17, 2008:
iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal
Mar 10, 2008:
iCo Therapeutics Provides iCo-008 Phase II Clinical Update
Feb 27, 2008:
iCo Therapeutics Announces CMO Invited to Present at International Ocular Conference
Jan 21, 2008:
iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Update
Copyright 2015 ICO Therapeutics | Disclaimer